Globe Newswire

U.S. Patent and Trademark Office Grants US Patent # 11,975,112 for “Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine” May 20, 2024 10:36AM

• Olanzapine (ZYPREXA®) is an antipsychotic medication used to treat schizophrenia and bipolar disorder that is commonly used as anti-nausea off label medication.
• Olanzapine has been investigated for use as an antiemetic at oral doses of 10 mg and 5 mg a day, generally in combination with one or more further agents to treat nausea and vomiting after administration of cisplatin.
• STAR-OLZ is being developed for CINV and is ready to enter a Phase 2 clinical trial. STAR-OLZ... (continue reading...)

Vivante Health Study Finds Digital Digestive Care Supports Health Equity, Presents Findings at Digestive Disease Week 2024 May 20, 2024 10:30AM

Nationally recognized specialists explored the effectiveness of digital digestive care for diverse and socially vulnerable populations

CHICAGO, May 20, 2024 (GLOBE NEWSWIRE) -- Vivante Health, the employee benefit for digestive care, today announced the presentation of results from its latest clinical study at Digestive Disease Week® (DDW) 2024. Presented by Dr. Hau Liu, Vivante Health's Chief Medical Officer, the findings cover the impact of Vivante Health’s... (continue reading...)

Consolidated results of the EPSO-G Group for Q1 2024 May 20, 2024 10:30AM

EPSO-G, a group of energy transmission and exchange companies (company code 302826889), with its registered office located at Laisvės pr. 10, Vilnius, Lithuania.

EPSO-G publishes the consolidated operating results of the Group, which includes the holding company EPSO-G, as well as its subsidiaries: Amber Grid, Baltpool, Energy Cells, Litgrid, and Tetas for the first three months of 2024.

Key financial indicators for 3 months:

Key financial indicatorsQ1 2024Q1... (continue reading...)

Correction: Form 8.3 - Mattioli Woods May 20, 2024 10:26AM

AMENDED DISCLOSURE - PLEASE REFER TO SECTIONS 2(a) AND 3(a)

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle... (continue reading...)

Form 8.3 - Mattioli Woods May 20, 2024 10:20AM

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor... (continue reading...)